Inhibition of tace activity enhances the susceptibility of myeloma cells to TRAIL

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Kagawa, Kumiko ^a   Nakano, Ayako ^a   Miki, Hirokazu ^a   Oda, Asuka ^a   Amou, Hiroe ^a   Takeuchi, Kyoko ^a   Nakamura, Shingen ^a   Harada, Takeshi ^a   Fujii, Shiro ^a   Yata, Kenichiro ^a   Ozaki, Shuji ^b   Matsumoto, Toshio ^a   Abe, Masahiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; ADAM PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ECTODOMAIN SHEDDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MYELOMA CELL; OSTEOCLAST; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; CELL STRAIN HL 60; CELL STRAIN U937; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; METABOLISM; MULTIPLE MYELOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADAM PROTEINS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; MULTIPLE MYELOMA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; U937 CELLS;

EID: 84857602657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031594     Document Type: Article

References (29)

1. Gonzalvez F, Ashkenazi A, (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29: 4752-4765.
2. Johnstone RW, Frew AJ, Smyth MJ, (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
3. Mellier G, Huang S, Shenoy K, Pervaiz S, (2010) TRAILing death incancer. Mol Aspects Med 31: 93-112.
4. Wiezorek J, Holland P, Graves J, (2010) Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 16: 1701-1708.
5. Moretto P, Hotte SJ, (2009) Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. Expert Opin Investig Drugs 18: 311-325.
6. Bellail AC, Qi L, Mullligan P, Chhabra V, Hao C, (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4: 34-41.
7. Buchsbaum DJ, Forero-Torres A, LoBuglio AF, (2007) TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol 3: 405-409.
8. Black RA, Rauch CT, Peschon CJ, Peschon JJ, Slack JL, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733.
9. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM, (2005) Shedding light on ADAM metalloproteinases. Trends Biochem Sci 30: 413-422.
10. Ahonen M, Poukkula M, Barker AH, Kashiwagi M, Nagase H, et al. (2003) Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 22: 2121-2134.
11. David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S, (2008) Perifosinesynergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res 14: 5090-5098.
12. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, et al. (2003) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21: 5673-5683.
13. Romagnoli M, Desplanques G, Maïga S, Legouill S, Dreano M, et al. (2007) Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin Cancer Res 13: 6010-6018.
14. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, et al. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98: 11581-11586.
15. Shipman CM, Croucher PI, (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912-916.
16. Secchiero P, Zauli G, (2008) Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 15: 42-48.
17. Mizrahi K, Stein J, Pearl-Yafe M, Kaplan O, Yaniv I, et al. (2010) Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation. Leukemia 24: 1325-1334.
18. Hiasa M, Abe M, Nakano A, Oda A, Amou H, et al. (2009) GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 114: 4517-4526.
19. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, et al. (2007) Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 90: 369-379.
20. Seals DF, Courtneidge SA, (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30.
21. Pratt G, Goodyear O, Moss P, (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138: 563-579.
22. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC, (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
23. Kitazoe K, Abe M, Hiasa M, Oda A, Amou H, et al. (2009) Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol 89: 45-57.
24. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, et al. (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role of for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13: 816-823.
25. Zdzisinska B, Bojarska-Junak A, Dmoszynska A, Kanderfer-Szerszen M, (2008) Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) 56: 207-221.
26. Benoit V, Chariot A, Delacroix L, Deregowski V, Jacobs N, (2004) Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression. Cancer Res 64: 2684-2691.
27. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J, (2001) NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21: 5299-5305.
28. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, et al. (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100: 2195-2202.
29. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, et al. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484-2491.